Big tech is wobbling. Goldman Sachs says it's time to buy these 23 unloved stocks instead.
Goldman Sachs says consumer-facing laggard stocks are the best way forward as earnings growth is set to slow next year and big tech stocks struggle.
Fiscal Year: January - December
Abbott Laboratories (ABT), listed on the NYSE, has a market capitalization of $179.53B. As of Oct 20, 2026, the stock is trading at $103.75 per share@else an unavailable price , offering investors a clear view of its current market value. Abbott Laboratories is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 33.67, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Abbott Laboratories also offers a dividend yield of 2.43%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Abbott Laboratories (ABT) has a DCF fair value that is only shown to premium members. To see it, please Login or Upgrade for access.
The proprietary SS Score for Abbott Laboratories is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Abbott Laboratories, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Abbott Laboratories is 23.01, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Abbott Laboratories (ABT) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Abbott Laboratories (ABT) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Abbott Laboratories (ABT) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Abbott Laboratories. To access the full SS Score, consider upgrading your subscription.
Abbott Laboratories is a significant player in the industry sector, with a market capitalization of $179.53B and a competitive P/E ratio of 33.67. Investors should compare these metrics with industry peers to gauge whether Abbott Laboratories is outperforming or underperforming within its sector.
Goldman Sachs says consumer-facing laggard stocks are the best way forward as earnings growth is set to slow next year and big tech stocks struggle.
New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support muscle recovery‡* and 3 grams of calcium HMB (beta-hydroxy-beta-methylbuty...
Barclays initiated coverage of Abbott (ABT) with an Overweight rating and $120 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive rating.
Abbott (ABT) announced U.S. FDA approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App. For the first time, care teams can…
For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can sig...
Rothschild & Co Redburn upgraded Abbott (ABT) to Buy from Neutral with a price target of $127, up from $119. The company’s acquisition of Exact Sciences has strengthened its diagnostics…
ABBOTT PARK, Ill., Sept. 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2026 financial results on Wednesday, Oct. 21, before the market opens.
Abbott (ABT) announced the U.S. commercial launch of SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the…
Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help eligib...
Abbott (ABT) and Berry Street announced an exclusive partnership to help people take a more proactive approach to nutrition and long-term health. The partnership brings together Lingo, Abbott’s consum...
Partnership combines Abbott's Lingo continuous glucose monitor with Berry Street's insurance-covered registered dietitian support, helping consumers translate glucose insights into healthier behaviors...
ABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
Abbott (ABT) announced that its Volt Pulsed Field Ablation System, designed to deliver more precise, targeted energy with fewer catheter exchanges and reduced radiation exposure than earlier-generatio...
Abbott (ABT) confirmed the company has reached an agreement to resolve the previously disclosed investigation and lawsuit brought by the United States Department of Justice, as well as lawsuits filed…
Abbott Laboratories has agreed to pay more than $384 million to settle allegations related to contaminated infant formula, the U.S. Justice Department said on Monday.
Settlement does not represent any finding of fault or liability As the government has previously indicated, it has closed its criminal investigation on this matter Tests by government regulators of un...
Abbott (ABT) Laboratories has agreed to pay $384,999,040 to resolve allegations that it caused false claims to be submitted between Jan. 1, 2018, and Dec. 31, 2022, to federal and…
Abbott (ABT) has received FDA approval for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat patients with challenging cases of atrial fibrillation, or AFib. Abbott will soon begin cases…
Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases St...
New Similac 360 Total Care Made With Whole Milk combines creamy whole milk for a fat blend that more closely resembles the fats in breast milk and five immune-nourishing prebiotics to help support bab...
Abbott (ABT) has received CE Mark for the Amulet 360 Left Atrial Appendage Occluder, a next-generation device designed to reduce risk of stroke in patients with atrial fibrillation not caused…
Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication Amulet 360 builds upon Abbott's first-generation LAA device with design updat...
The U.S. Food and Drug Administration said on Tuesday it authorized Abbott Laboratories' glucose monitor, making it the first device that continuously monitors both ketone levels and blood sugar.
Abbott (ABT) announced U.S. Food and Drug Administration authorization of its Libre Duo 10 Day system, the world’s first dual glucose-ketone sensing technology. The new biowearable is designed to aler...
Projected from reported cash flow (SEC filings). The starting point is the latest yearly revenue times the median free cash flow margin of the last five years. Years 1 to 5 grow at the revenue growth rate of the last five years (between -5% and 15%), and years 6 to 10 slow down to the 2.5% perpetual growth rate. These are Studying Stocks' own estimates, not analyst forecasts, and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | Source |
|---|---|---|---|
| 2026 | 7.77B | 5.08% | Projected |
| 2027 | 8.16B | 5.08% | Projected |
| 2028 | 8.58B | 5.08% | Projected |
| 2029 | 9.01B | 5.08% | Projected |
| 2030 | 9.47B | 5.08% | Projected |
| 2031 | 9.90B | 4.56% | Projected |
| 2032 | 10.30B | 4.05% | Projected |
| 2033 | 10.67B | 3.53% | Projected |
| 2034 | 10.99B | 3.02% | Projected |
| 2035 | 11.26B | 2.50% | Projected |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 6.35B | 1.00 | 6.35B |
| 2025A | 7.40B | 1.00 | 7.40B |
| 2026E | 7.77B | 1.08 | Login |
| 2027E | 8.16B | 1.17 | Login |
| 2028E | 8.58B | 1.26 | Login |
| 2029E | 9.01B | 1.36 | Login |
| 2030E | 9.47B | 1.47 | Login |
| 2031E | 9.90B | 1.58 | Login |
| 2032E | 10.30B | 1.71 | Login |
| 2033E | 10.67B | 1.85 | Login |
| 2034E | 10.99B | 2.00 | Login |
| 2035E | 11.26B | 2.15 | Login |
| Terminal | 2.15 | Login |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.